Literature DB >> 27618742

Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules.

K Magalon1, M Le Grand2, B El Waly1, M Moulis3, R Pruss4, T Bordet4, M Cayre1, P Belenguer3, M Carré2, P Durbec5.   

Abstract

Multiple sclerosis (MS) is a neurodegenerative disease characterized by episodes of immune attacks and oligodendrocyte death leading to demyelination and progressive functional deficits. New therapeutic strategies are needed to stimulate the spontaneous regenerative process observed in some patients. Spontaneous myelin repair relies on the mobilization and differentiation of endogenous oligodendrocyte progenitors at the lesion site. Olesoxime, a cholesterol-like compound, has been shown to favor oligodendrocyte maturation in culture and promote myelin regeneration in rodents. Here, we study the mode of action of this compound and show that it binds to oligodendrocyte mitochondria, leading to their hyperfilamentation. This is accompanied by a reduction of basal superoxide levels, and accumulation of End Binding Protein 1 (EB1) at growing ends of microtubules. In parallel, we demonstrate that Reactive Oxygen Species (ROS) scavengers also promote oligodendrocyte differentiation, together with increasing mitochondrial filamentation and EB1-dependent microtubule polymerization. Altogether, our data uncover the mechanisms by which olesoxime promotes oligodendrocyte maturation. They also reveal that a bidirectional relationship between mitochondria hyperfilamentation and ROS level modulation controls oligodendrocyte maturation. This study identifies new cellular mechanisms to target for the development of regenerative treatments for MS.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell differentiation; Mdivi-1 (PubChem CID: 3825829); Microtubule dynamics; MitoTEMPO (PubChem CID: 54613387); Mitochondria; Olesoxime; Olesoxime (PubChem CID: 21763506); Oligodendrocyte; Paclitaxel (PubChem CID: 36314); Tiron (PubChem CID: 9001)

Mesh:

Substances:

Year:  2016        PMID: 27618742     DOI: 10.1016/j.neuropharm.2016.09.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC.

Authors:  Amandine Rovini; Philip A Gurnev; Alexandra Beilina; María Queralt-Martín; William Rosencrans; Mark R Cookson; Sergey M Bezrukov; Tatiana K Rostovtseva
Journal:  Cell Mol Life Sci       Date:  2019-11-23       Impact factor: 9.261

Review 2.  To mdivi-1 or not to mdivi-1: Is that the question?

Authors:  George Smith; Gianluca Gallo
Journal:  Dev Neurobiol       Date:  2017-08-30       Impact factor: 3.964

Review 3.  Mdivi-1: a promising drug and its underlying mechanisms in the treatment of neurodegenerative diseases.

Authors:  Xiaoqin Liu; Lijuan Song; Jiezhong Yu; Fang Huang; Yanhua Li; Cungen Ma
Journal:  Histol Histopathol       Date:  2022-02-24       Impact factor: 2.130

4.  Corrigendum: Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.

Authors:  Candice E Crocker; Philip G Tibbo
Journal:  Front Pharmacol       Date:  2018-12-04       Impact factor: 5.810

Review 5.  Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.

Authors:  Candice E Crocker; Philip G Tibbo
Journal:  Front Pharmacol       Date:  2018-10-18       Impact factor: 5.810

Review 6.  Myelin Repair: From Animal Models to Humans.

Authors:  Myriam Cayre; Marie Falque; Océane Mercier; Karine Magalon; Pascale Durbec
Journal:  Front Cell Neurosci       Date:  2021-04-14       Impact factor: 5.505

7.  Structural basis of cholesterol binding by a novel clade of dendritic cell modulators from ticks.

Authors:  Pietro Roversi; Steven Johnson; Stephen G Preston; Miles A Nunn; Guido C Paesen; Jonathan M Austyn; Patricia A Nuttall; Susan M Lea
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.